BibTex RIS Cite

MDAH-2774 İnsan Over Kanseri Üç Boyutlu Hücre Kültüründe Farklı İlaç Etkilerinin Nitrik Oksit Sentaz Değişiklikleri ile İncelenmesi

Year 2009, Volume: 40 Issue: 3, 88 - 96, 15.11.2013

Şule Ayla Gülperi Öktem Ayhan Bilir Şule Ayla Ayhan Bilir

Keywords

İndüklenebilir nitrik oksit sentaz endotelial nitrik oksit sentaz MDAH-2774 gemsitabine resveratrol parasetamol

References

  • 1. Alt›nöz MA, Bilir A. Inflamation, nonsteroid and steroid anti-inflammatory agents and ovarian cancer In: Bardos PA, ed. Treatment of Ovarian Cancer. New York: Nova Science Publishers; 2005. p. 97-111.
  • 2. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327-336.
  • 3. Kayaalp O. Rasyonel Tedavi Yönünden Tibbi Farmakoloji. Ankara: Günefl Bas›mevi; 2000.
  • 4. Gemcitabine® , Preparat reçetesi ( Lilly).
  • 5. Ali S, El-Rayes BF, Aranha O, Sarkar FH, Philip PA. Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer Cells. Breast Cancer Res Treat 2005; 90: 25-31.
  • 6. ‹kizler M, Dernek S, Erkasap N, Kayg›s›z Z, Sevin B, Kural T. The hemodynamic efficacy of resveratrol on reperfüzyon. Injury in isolated rat hearts. Türk Gö¤üs Kalp Damar Cerrahisi Dergisi 2003; 11: 91-99.
  • 7. Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 2005; 4: 49.
  • 8. Aggarwal BB, Shishir S. Molecular targets of dietary agents for prevention and therapy of cancer. J Biochem Pharmacol 2006; 71: 1397-1421.
  • 9. ‹gnorro JJ, Byrns RE, Wood KS. Biochemical and pharmacological propeties of endothelium-derived relaxing factor and its smilarity to nitric oxide radicals. In: Vanhoutte PM, ed. Vasodilatation. New York: Raven Press; 1998. p. 427-436.
  • 10. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endotelium derived relaxing factors. Nature 1988; 327: 524-526.
  • 11. Vakkala M, Kahlos K, Lakkari E, Paakko P. Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carsinoma. Clin Canser Res 2000; 6: 2408-2416.
  • 12. fiahin F, Avcu F, Saydam G, ve ark. K›rm›z› üzüm çekirde¤i ekstrakt› ve ana bileflenlerinden resveratrol ve boraks malign hücre dizileri üzerinde sitotoksik etki göstermektedir. Turkish Journal of Haematology; 2004; 21 Suppl 3: 53-54. [Abstract]
  • 13. http://en.wikipedia.org/wiki/Resveratrol
  • 14. Benitez DA, Pozo-Guisado E, Alvarez-Barrientos A, Fernandez-Salguero PM, Castellon EA. Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J Androl 2006; 7: 333-335.
  • 15. Riles WL, Erickson J, Nayyar S, Atten MJ, Attar BM, Holian O. Resveratrol engages selective apoptotic signals in gastric adenocarcinoma cells. World J Gastroenterol 2006; 12: 5628-5634.
  • 16. Turna H., Demir G. Pankreas Kanseri Tedavisine Medikal Onkolojik Yaklafl›m. ‹stanbul: ‹.Ü. Cerrahpafla T›p Fakültesi Sürekli T›p E¤itim Etkinlikleri; 2002. s. 231-236.
  • 17. Zhu GH, Wong BCY, Ching CK, Lai KC, Lam SK. Differential apoptosis by indomethacin in gastric epithelial cells Trough the constiyuve expression of wild-Type p53 and/or Up-regulation of c-myc. Biochem Pharmacol 1999; 58: 193-200.
  • 18. Bernardi A, Jacques- Silva MC, Delgada- Canedo A, Lenz G, Battastini M. Nonsteroidal anti- inflammatory drugs inhibit the growth of C6 and U138-MG glioma Cell Lines. Eur J Pharmacol; 2006; 532: 214-222.
  • 19. Joki T, Carrol RS, Dunn IF, Zhang J, Abe T, Black PM. Assesment of alteration in gene expression in reccurrent malignant glioma after radiotherapy using complemantary deoxyribonucleic acid microarrays. Neurosurgery 2001; 48: 195-201.
  • 20. Özdemirler G, Aykaç G, Uysal M, et al. Liver lipid peroxidation and glutathione-related defence enzyme systems in mice treated with paracetamol. J Appl Toxicol 1994; 14: 297-299.
  • 21. Bilir A, Altinoz MA, Atar E, Erkan M, Ayd›ner A. Acetaminophen modulations of chemotherapy efficacy in MDAH 2774 human endometrioid ovarian cancer cells in vitro. Neoplasma 2002; 49: 38-42.
  • 22. Yip-Schneider TM., Sweeney J, Jung S, Crowell PL, Marshall MS. Cell cycle effects of nonsteroidal antiinflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther 2001; 298: 976-985.
  • 23. Öktem G. MCF-7 ‹nsan Meme Kanseri Hücre Hatt›nda Doksorubisin ve Dositakselin Sitotoksisitesi ve ‹ndüklenebilir Nitrik Oksit Sentaz Ekspresyonu Üzerine Etkileri. Uzmanl›k Tezi. ‹zmir: Ege Ü. T›p Fakültesi Histoloji ve Embriyoloji Anabilim Dal›: 2002.
  • 24. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992; 6: 3051-3064.
  • 25. Farais-Eisner R, Sherman MP, Aeberhard E, et al. Nitric oxide is an important mediator for tumorocidal activity in vivo. Proc Natl Acad Sci USA 1994; 91: 9407- 9411.
  • 26. Stuehr DJ, Nathan JF. Nitric oxide: a macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 1989; 169: 1543-1545.
  • 27. Thomsen LJ, Lawton FG, Knowles RG. Nitric oxide synthase activity in human gynecological cancer. Cancer Res 1994; 54: 1352-1354.
  • 28. Thomsen LJ, Scott JMJ, Topley P, Knowles RG, Keerie AJ, Frend AJ. Selective inhibition of inducible nitric oxide sythase inhibits tumor growth in vivo: studies with 1400 W, a novel inhibitor. Cancer Res 1997; 57: 3300-3304.
  • 29. Xie K, Huang S, Dong Z, Gutman M. Direct correlation between expression of endogenous inducible nitric oxide synthase and regression of M5076 reticulum cell sarcoma hepatic metastases in mice treated with liposomes containing lipopeptide CGP 31362. Cancer Res 1995; 55: 3123-3131.
  • 30. Thomsen LL, Miles DW. Role of nitric oxide in tumor progression: Lessons from human tumors. Cancer and Met Rew 1998; 17: 107-118.
  • 31. Lechner M, Lirk P,Rieder J. Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Semin Cancer Biol 2005; 15: 277-89.
  • 32. Darh A, Brindley JM, Stark C, Citro ML, Keefer LK. Nitric oxide does not mediate but inhibits transformation and tumor phenotype. Mol Cancer Ther 2003; 2: 1285-1293.
  • 33. Zeybek DN, Inan S, Ekerb›cer N, Vatansever SH. The effects of gemcitabine and vinoralbine on inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) distribution of MCF-7 breast cancer cells. Acta Histochem 2009; doi:10.1016/j.acthis.2009.07.006
  • 34. Cooper MG, Hausman ER. Hücre - Moleküler Yaklafl›m. Çev. ed.: Sak›zl› M, Atabey N. ‹zmir: ‹zmir T›p Kitabevi; 2006. s. 664-665.

Year 2009, Volume: 40 Issue: 3, 88 - 96, 15.11.2013

Şule Ayla Gülperi Öktem Ayhan Bilir Şule Ayla Ayhan Bilir

References

  • 1. Alt›nöz MA, Bilir A. Inflamation, nonsteroid and steroid anti-inflammatory agents and ovarian cancer In: Bardos PA, ed. Treatment of Ovarian Cancer. New York: Nova Science Publishers; 2005. p. 97-111.
  • 2. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327-336.
  • 3. Kayaalp O. Rasyonel Tedavi Yönünden Tibbi Farmakoloji. Ankara: Günefl Bas›mevi; 2000.
  • 4. Gemcitabine® , Preparat reçetesi ( Lilly).
  • 5. Ali S, El-Rayes BF, Aranha O, Sarkar FH, Philip PA. Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer Cells. Breast Cancer Res Treat 2005; 90: 25-31.
  • 6. ‹kizler M, Dernek S, Erkasap N, Kayg›s›z Z, Sevin B, Kural T. The hemodynamic efficacy of resveratrol on reperfüzyon. Injury in isolated rat hearts. Türk Gö¤üs Kalp Damar Cerrahisi Dergisi 2003; 11: 91-99.
  • 7. Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 2005; 4: 49.
  • 8. Aggarwal BB, Shishir S. Molecular targets of dietary agents for prevention and therapy of cancer. J Biochem Pharmacol 2006; 71: 1397-1421.
  • 9. ‹gnorro JJ, Byrns RE, Wood KS. Biochemical and pharmacological propeties of endothelium-derived relaxing factor and its smilarity to nitric oxide radicals. In: Vanhoutte PM, ed. Vasodilatation. New York: Raven Press; 1998. p. 427-436.
  • 10. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endotelium derived relaxing factors. Nature 1988; 327: 524-526.
  • 11. Vakkala M, Kahlos K, Lakkari E, Paakko P. Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carsinoma. Clin Canser Res 2000; 6: 2408-2416.
  • 12. fiahin F, Avcu F, Saydam G, ve ark. K›rm›z› üzüm çekirde¤i ekstrakt› ve ana bileflenlerinden resveratrol ve boraks malign hücre dizileri üzerinde sitotoksik etki göstermektedir. Turkish Journal of Haematology; 2004; 21 Suppl 3: 53-54. [Abstract]
  • 13. http://en.wikipedia.org/wiki/Resveratrol
  • 14. Benitez DA, Pozo-Guisado E, Alvarez-Barrientos A, Fernandez-Salguero PM, Castellon EA. Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J Androl 2006; 7: 333-335.
  • 15. Riles WL, Erickson J, Nayyar S, Atten MJ, Attar BM, Holian O. Resveratrol engages selective apoptotic signals in gastric adenocarcinoma cells. World J Gastroenterol 2006; 12: 5628-5634.
  • 16. Turna H., Demir G. Pankreas Kanseri Tedavisine Medikal Onkolojik Yaklafl›m. ‹stanbul: ‹.Ü. Cerrahpafla T›p Fakültesi Sürekli T›p E¤itim Etkinlikleri; 2002. s. 231-236.
  • 17. Zhu GH, Wong BCY, Ching CK, Lai KC, Lam SK. Differential apoptosis by indomethacin in gastric epithelial cells Trough the constiyuve expression of wild-Type p53 and/or Up-regulation of c-myc. Biochem Pharmacol 1999; 58: 193-200.
  • 18. Bernardi A, Jacques- Silva MC, Delgada- Canedo A, Lenz G, Battastini M. Nonsteroidal anti- inflammatory drugs inhibit the growth of C6 and U138-MG glioma Cell Lines. Eur J Pharmacol; 2006; 532: 214-222.
  • 19. Joki T, Carrol RS, Dunn IF, Zhang J, Abe T, Black PM. Assesment of alteration in gene expression in reccurrent malignant glioma after radiotherapy using complemantary deoxyribonucleic acid microarrays. Neurosurgery 2001; 48: 195-201.
  • 20. Özdemirler G, Aykaç G, Uysal M, et al. Liver lipid peroxidation and glutathione-related defence enzyme systems in mice treated with paracetamol. J Appl Toxicol 1994; 14: 297-299.
  • 21. Bilir A, Altinoz MA, Atar E, Erkan M, Ayd›ner A. Acetaminophen modulations of chemotherapy efficacy in MDAH 2774 human endometrioid ovarian cancer cells in vitro. Neoplasma 2002; 49: 38-42.
  • 22. Yip-Schneider TM., Sweeney J, Jung S, Crowell PL, Marshall MS. Cell cycle effects of nonsteroidal antiinflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther 2001; 298: 976-985.
  • 23. Öktem G. MCF-7 ‹nsan Meme Kanseri Hücre Hatt›nda Doksorubisin ve Dositakselin Sitotoksisitesi ve ‹ndüklenebilir Nitrik Oksit Sentaz Ekspresyonu Üzerine Etkileri. Uzmanl›k Tezi. ‹zmir: Ege Ü. T›p Fakültesi Histoloji ve Embriyoloji Anabilim Dal›: 2002.
  • 24. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992; 6: 3051-3064.
  • 25. Farais-Eisner R, Sherman MP, Aeberhard E, et al. Nitric oxide is an important mediator for tumorocidal activity in vivo. Proc Natl Acad Sci USA 1994; 91: 9407- 9411.
  • 26. Stuehr DJ, Nathan JF. Nitric oxide: a macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 1989; 169: 1543-1545.
  • 27. Thomsen LJ, Lawton FG, Knowles RG. Nitric oxide synthase activity in human gynecological cancer. Cancer Res 1994; 54: 1352-1354.
  • 28. Thomsen LJ, Scott JMJ, Topley P, Knowles RG, Keerie AJ, Frend AJ. Selective inhibition of inducible nitric oxide sythase inhibits tumor growth in vivo: studies with 1400 W, a novel inhibitor. Cancer Res 1997; 57: 3300-3304.
  • 29. Xie K, Huang S, Dong Z, Gutman M. Direct correlation between expression of endogenous inducible nitric oxide synthase and regression of M5076 reticulum cell sarcoma hepatic metastases in mice treated with liposomes containing lipopeptide CGP 31362. Cancer Res 1995; 55: 3123-3131.
  • 30. Thomsen LL, Miles DW. Role of nitric oxide in tumor progression: Lessons from human tumors. Cancer and Met Rew 1998; 17: 107-118.
  • 31. Lechner M, Lirk P,Rieder J. Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Semin Cancer Biol 2005; 15: 277-89.
  • 32. Darh A, Brindley JM, Stark C, Citro ML, Keefer LK. Nitric oxide does not mediate but inhibits transformation and tumor phenotype. Mol Cancer Ther 2003; 2: 1285-1293.
  • 33. Zeybek DN, Inan S, Ekerb›cer N, Vatansever SH. The effects of gemcitabine and vinoralbine on inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) distribution of MCF-7 breast cancer cells. Acta Histochem 2009; doi:10.1016/j.acthis.2009.07.006
  • 34. Cooper MG, Hausman ER. Hücre - Moleküler Yaklafl›m. Çev. ed.: Sak›zl› M, Atabey N. ‹zmir: ‹zmir T›p Kitabevi; 2006. s. 664-665.
There are 34 citations in total.

Details

Primary Language Turkish
Journal Section Araştırmalar
Authors

Şule Ayla This is me

Gülperi Öktem This is me

Ayhan Bilir This is me

Şule Ayla Ayhan Bilir This is me

Publication Date November 15, 2013
Published in Issue Year 2009 Volume: 40 Issue: 3

Cite

APA Ayla, Ş., Öktem, G., Bilir, A., Ayhan Bilir, Ş. A. (2013). MDAH-2774 İnsan Over Kanseri Üç Boyutlu Hücre Kültüründe Farklı İlaç Etkilerinin Nitrik Oksit Sentaz Değişiklikleri ile İncelenmesi. Cerrahpaşa Tıp Dergisi, 40(3), 88-96.
AMA Ayla Ş, Öktem G, Bilir A, Ayhan Bilir ŞA. MDAH-2774 İnsan Over Kanseri Üç Boyutlu Hücre Kültüründe Farklı İlaç Etkilerinin Nitrik Oksit Sentaz Değişiklikleri ile İncelenmesi. Cerrahpaşa Tıp Dergisi. November 2013;40(3):88-96.
Chicago Ayla, Şule, Gülperi Öktem, Ayhan Bilir, and Şule Ayla Ayhan Bilir. “MDAH-2774 İnsan Over Kanseri Üç Boyutlu Hücre Kültüründe Farklı İlaç Etkilerinin Nitrik Oksit Sentaz Değişiklikleri Ile İncelenmesi”. Cerrahpaşa Tıp Dergisi 40, no. 3 (November 2013): 88-96.
EndNote Ayla Ş, Öktem G, Bilir A, Ayhan Bilir ŞA (November 1, 2013) MDAH-2774 İnsan Over Kanseri Üç Boyutlu Hücre Kültüründe Farklı İlaç Etkilerinin Nitrik Oksit Sentaz Değişiklikleri ile İncelenmesi. Cerrahpaşa Tıp Dergisi 40 3 88–96.
IEEE Ş. Ayla, G. Öktem, A. Bilir, and Ş. A. Ayhan Bilir, “MDAH-2774 İnsan Over Kanseri Üç Boyutlu Hücre Kültüründe Farklı İlaç Etkilerinin Nitrik Oksit Sentaz Değişiklikleri ile İncelenmesi”, Cerrahpaşa Tıp Dergisi, vol. 40, no. 3, pp. 88–96, 2013.
ISNAD Ayla, Şule et al. “MDAH-2774 İnsan Over Kanseri Üç Boyutlu Hücre Kültüründe Farklı İlaç Etkilerinin Nitrik Oksit Sentaz Değişiklikleri Ile İncelenmesi”. Cerrahpaşa Tıp Dergisi 40/3 (November 2013), 88-96.
JAMA Ayla Ş, Öktem G, Bilir A, Ayhan Bilir ŞA. MDAH-2774 İnsan Over Kanseri Üç Boyutlu Hücre Kültüründe Farklı İlaç Etkilerinin Nitrik Oksit Sentaz Değişiklikleri ile İncelenmesi. Cerrahpaşa Tıp Dergisi. 2013;40:88–96.
MLA Ayla, Şule et al. “MDAH-2774 İnsan Over Kanseri Üç Boyutlu Hücre Kültüründe Farklı İlaç Etkilerinin Nitrik Oksit Sentaz Değişiklikleri Ile İncelenmesi”. Cerrahpaşa Tıp Dergisi, vol. 40, no. 3, 2013, pp. 88-96.
Vancouver Ayla Ş, Öktem G, Bilir A, Ayhan Bilir ŞA. MDAH-2774 İnsan Over Kanseri Üç Boyutlu Hücre Kültüründe Farklı İlaç Etkilerinin Nitrik Oksit Sentaz Değişiklikleri ile İncelenmesi. Cerrahpaşa Tıp Dergisi. 2013;40(3):88-96.